🏛️ Verified NIH Record • Updated 2026-07-24
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors (NCT06781983)
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Innate Pharma
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital - Boston — Boston, Massachusetts
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Massachusetts General Hospital - Boston — Boston, Massachusetts
- John Theurer Cancer Center — Hackensack, New Jersey
- Mount Sinai Tisch Cancer Center — New York, New York
- NEXT Oncology - Dallas — Dallas, Texas
- NEXT Oncology - Virginia — Fairfax, Virginia
- Centre Léon Bérard — Lyon,
- Gustave Roussy Cancer Institute — Villejuif,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.